Joaquín Castilló

Modulation of immune cell reactivity with cis -binding Siglec agonists

Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM

The cerebellum and cognition

Levodopa‐induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [¹¹C]raclopride displacement and PET

Purification and Identification of Activating Enzymes of CS-0777, a Selective Sphingosine 1-Phosphate Receptor 1 Modulator, in Erythrocytes

Similarities and differences in surface receptor expression by THP-1 monocytes and differentiated macrophages polarized using seven different conditioning regimens

Effects of the substituted (S)-3-phenylpiperidine (−)-OSU6162 on PET measurements of [11C]SCH23390 and [11C]raclopride binding in primate brains

Diagnosis of multiple sclerosis: progress and challenges

Identification of a Metabolizing Enzyme in Human Kidney by Proteomic Correlation Profiling

MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—clinical implementation in the diagnostic process

The role of the cerebellum in multiple sclerosis—150 years after Charcot

Is it time to target no evident disease activity (NEDA) in multiple sclerosis?

Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis

Defining Disease Activity and Response to Therapy in MS

Effects of the substituted (S)-3-phenylpiperidine (?)-OSU6162 on PET measurements in subhuman primates: Evidence for tone-dependent normalization of striatal dopaminergic activity

Synthesis and biological evaluation of 9-N-oxamyl sialosides as Siglec-7 ligands

Multiple Sclerosis: New Insights in Pathogenesis and Novel Therapeutics

Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases

Accurate Proteome-wide Label-free Quantification by Delayed Normalization and Maximal Peptide Ratio Extraction, Termed MaxLFQ

Biomarkers in multiple sclerosis

Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing−remitting multiple sclerosis: A retrospective analysis

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue

Multiple Sclerosis

Natural product and natural product derived drugs in clinical trials

Clinical Practice Guideline: Sudden Hearing Loss (Update)

Monosymptomatic Clinically Isolated Syndrome With Sudden Sensorineural Hearing Loss

Multiple sclerosis in Chile

Fingolimod for relapsing multiple sclerosis: an update

Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response

Clinical impact of early brain atrophy in clinically isolated syndromes

Should we systematically test patients with clinically isolated syndrome for auto-antibodies?

Measures in the first year of therapy predict the response to interferon β in MS

Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes

Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis

Value of NMO-IgG determination at the time of presentation as CIS

Brainstem lesions in clinically isolated syndromes

SIGLEC1 and SIGLEC7 expression in circulating monocytes of patients with multiple sclerosis